Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.